L2: Update LINKS
我们是谁
表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞（FH-A11KRASG12V-TCR）用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者
无病变证据 (NED) 的 IV 期结直肠癌患者的 Durvalumab 加瑞戈非尼辅助治疗与未治疗对照组对比：VIVA 试验
Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients
晚期或转移性实体瘤 NGM831 单药及与 Pembrolizumab 联合用药研究
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
